Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
The bill creates a new federal crime for medical research companies or sponsors who make or conceal fraudulent material statements about clinical vaccine trial data, punishable by fines and up to five years imprisonment. It conditions Emergency Use Authorizations and some liability protections on a sponsor certification that no fraud occurred, authorizes revocation for fraud, and carves out exceptions to pandemic/epidemic liability shields and Right-to-Try protections where fraudulent trial data is found.
Due process: liberals want protections; conservatives worry about executive power.
Relative to its intended legislative type, this bill is substantively ambitious and targeted—creating a new federal offense and altering major liability and emergency-use statutory schemes—but its drafting leaves significant gaps in definitions, standards, procedural safeguards, and fiscal acknowledgement that reduce clarity and raise implementation questions.
The bill creates a new federal crime for medical research companies or sponsors who make or conceal fraudulent material statements about clinical vaccine trial data, punishable by fines and up to five years imprisonment.
It conditions Emergency Use Authorizations and some liability protections on a sponsor certification that no fraud occurred, authorizes revocation for fraud, and carves out exceptions to pandemic/epidemic liability shields and Right-to-Try protections where fraudulent trial data is found.
It amends the National Vaccine Injury Compensation Program to allow civil actions and concurrent district-court suits when the Secretary determines fraud, including a perpetual COVID-19-specific applicability.
Substantive rollback of federal liability protections for vaccines and criminalization is high‑conflict; lacks clear bipartisan compromise features.
Relative to its intended legislative type, this bill is substantively ambitious and targeted—creating a new federal offense and altering major liability and emergency-use statutory schemes—but its drafting leaves significant gaps in definitions, standards, procedural safeguards, and fiscal acknowledgement that reduce clarity and raise implementation questions.
Due process: liberals want protections; conservatives worry about executive power.
These are examples from the analysis, not a ranked list of the most-affected groups.
Due process: liberals want protections; conservatives worry about executive power.
Likely supportive of stronger accountability for companies that falsify vaccine trial data, seeing it as protecting public health and safety.
Would be attentive to civil-justice access expansions but cautious about due process specifics and potential misuse to amplify anti-vaccine claims.
Generally favorable toward accountability for fraudulent clinical trial behavior while seeking stronger procedural safeguards and clearer legal standards.
Will weigh benefits to public trust against risks of chilling innovation and burdens on emergency authorizations.
Mixed reaction: approval for greater corporate accountability and removal of some liability shields, but skepticism about creating new federal crimes and expanding HHS authority.
Concerned about federal overreach, harm to innovation, and procedural fairness.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive rollback of federal liability protections for vaccines and criminalization is high‑conflict; lacks clear bipartisan compromise features.
The bill has not accumulated any surfaced votes yet.
Due process: liberals want protections; conservatives worry about executive power.
Substantive rollback of federal liability protections for vaccines and criminalization is high‑conflict; lacks clear bipartisan compromise…
Relative to its intended legislative type, this bill is substantively ambitious and targeted—creating a new federal offense and altering major liability and emergency-use statutory schemes—but its drafting leaves signif…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.